Limb Girdle Muscular Dystrophy (LGMD) Market to Exhibit Moderate Growth Rate till 2032, Investigates DelveInsight
DelveInsight’s “Limb Girdle Muscular Dystrophy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Limb Girdle Muscular Dystrophy market size, share, and trends in the seven major market (7MM) (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan).
The Limb Girdle Muscular Dystrophy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Limb Girdle Muscular Dystrophy: An Overview
Limb Girdle Muscular Dystrophy is a diverse group of disorders with many subtypes categorized by disease gene and inheritance. LGMD usually manifests in the proximal muscles around the hips and shoulders. (The proximal muscles are those closest to the center of the body; distal muscles are farther away from the center — for example, in the hands and feet).
The genes associated with LGMD normally encode proteins that play vital roles in muscle function, regulation, and repair. When one of these genes contains a mutation (a flaw, such as missing or incorrect information), cells cannot produce the proteins needed for healthy muscles.
The management of limb-girdle muscular dystrophy (LGMD) is supportive; no disease-modifying treatments are available. The therapeutic goal includes maintaining mobility and functional independence, managing associated complications, and maximizing quality of life.
Limb Girdle Muscular Dystrophy Market Key Facts
-
According to the NORD, Limb Girdle Muscular Dystrophy (LGMD) affects males and females equally. Estimates range the prevalence of LGMD from one in 14,500 to one in 123,000. The age of onset can vary greatly, even among individuals of the same family.
-
According to a study conducted by Wang et al. (2018), LGMD is the fourth most common muscular dystrophy, with a pooled prevalence of 1.63 per 100,000 people, following myotonic dystrophy, dystrophinopathy, and facioscapulohumeral dystrophy. The prevalence varies among subtypes and regions.
-
At present, there is no cure and no FDA-approved therapies for the treatment of Limb-Girdle Muscular Dystrophy (LGMD); current research is mostly focused on the use of novel gene therapies to treat the underlying genetic changes. Major pharmaceutical companies, such as Myonexus Therapeutics (MYO-101, MYO-102) and aTyr Pharma (ATYR1940), etc. are involved in the development of novel therapies for the treatment of Limb Girdle Muscular Dystrophy (LGMD).
Limb Girdle Muscular Dystrophy (LGMD) Market
The market outlook section of the report helps to build a detailed comprehension of the historical, current, and forecasted Limb Girdle Muscular Dystrophy market size by analyzing the impact of current and emerging pipeline therapies. It also provides a thorough assessment of the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Limb Girdle Muscular Dystrophy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MoA), Route of Administration (RoA), molecule types, competition with other therapies, brand value, and their impact on the market.
Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and and views of key opinion leaders.
Limb Girdle Muscular Dystrophy (LGMD) Epidemiology Segmentation –
-
Total prevalent Cases of Limb Girdle Muscular Dystrophy (LGMD)
-
Type-specific prevalent Cases of Limb Girdle Muscular Dystrophy (LGMD)
-
Gender-specific prevalent Cases of Limb Girdle Muscular Dystrophy (LGMD)
-
Diagnosed and Treatable cases of Limb Girdle Muscular Dystrophy (LGMD)
Limb Girdle Muscular Dystrophy (LGMD) Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Limb Girdle Muscular Dystrophy market or expected to get launched during the study period. The analysis covers the Limb Girdle Muscular Dystrophy market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Limb Girdle Muscular Dystrophy Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How Limb Girdle Muscular Dystrophy Market Will Evolve by 2032 @
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market
Limb Girdle Muscular Dystrophy (LGMD) Therapies covered in the report include –
-
BBP-418
-
SRP-9003
-
CAT-1004
-
ATYR1940
-
SRP-9005
And many more.
Some of the key companies in the Limb Girdle Muscular Dystrophy (LGMD) Market include –
-
ML Bio Solutions
-
Sarepta Therapeutics
-
Catabasis Pharmaceuticals
-
aTyr Pharma
And many others.
Further Emerging Drugs & Key Companies are Covered in the Report. Download the Sample PDF to Learn More @
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Limb Girdle Muscular Dystrophy Competitive Intelligence Analysis
4. Limb Girdle Muscular Dystrophy Market Overview at a Glance
5. Limb Girdle Muscular Dystrophy Disease Background and Overview
6. Limb Girdle Muscular Dystrophy Patient Journey
7. Limb Girdle Muscular Dystrophy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Limb Girdle Muscular Dystrophy Treatment Algorithm, Current Treatment, and Medical Practices
9. Limb Girdle Muscular Dystrophy Unmet Needs
10. Key Endpoints of Limb Girdle Muscular Dystrophy Treatment
11. Limb Girdle Muscular Dystrophy Marketed Products
12. Limb Girdle Muscular Dystrophy Emerging Drugs and Latest Therapeutic Advances
13. Limb Girdle Muscular Dystrophy Seven Major Market Analysis
14. Attribute Analysis
15. Limb Girdle Muscular Dystrophy Market Outlook (In US, EU5, and Japan)
16. Limb Girdle Muscular Dystrophy Access and Reimbursement Overview
17. KOL Views on the Limb Girdle Muscular Dystrophy Market
18. Limb Girdle Muscular Dystrophy Market Drivers
19. Limb Girdle Muscular Dystrophy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download Sample PDF to Explore the Key Offerings of the Report @
https://www.delveinsight.com/sample-request/limb-girdle-muscular-dystrophy-lgmd-market
Other Trending Healthcare Reports By DelveInsight
Limb Girdle Muscular Dystrophy (LGMD) Pipeline Insights
DelveInsight’s “Limb Girdle Muscular Dystrophy Pipeline Insight, 2022” report provides comprehensive insights about 20+ companies and 25+ drugs in the Limb Girdle Muscular Dystrophy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
